Neuromuscular Blocker Use in Critically Ill Children: Assessing Mortality Risk by Propensity Score-Weighted Analysis

Marco Daverio1,2, Francesca Sperotto1,2,3, Chiara Stefani2

  • 1Pediatric Intensive Care Unit, Department of Woman's and Child's Health, University Hospital, Padova, Italy.

Critical Care Medicine
|September 28, 2021
PubMed

Insights

Continuous neuromuscular blocking agent infusion in critically ill children is associated with higher in-hospital mortality. This finding highlights the need for careful consideration when using these agents in pediatric intensive care units (PICUs).

Area of Science:

  • Pediatric Critical Care Medicine
  • Pharmacology
  • Epidemiology

Background:

  • Neuromuscular blocking agents (NMBAs) are used in mechanically ventilated children.
  • The association between continuous NMBA infusion and outcomes in critically ill children is not well-defined.

Purpose of the Study:

  • To describe NMBA infusion use in pediatric intensive care units (PICUs).
  • To assess the association between continuous NMBA infusion and in-hospital mortality in mechanically ventilated children.

Main Methods:

  • Retrospective, observational study using prospectively collected data from a national registry (2010-2017).
  • Included 3,823 mechanically ventilated children (<18 years) from 17 Italian PICUs.
  • Propensity score-weighted Cox regression analysis was used to evaluate mortality risk.

Main Results:

  • Continuous NMBA infusion was used in 13% of patients.
  • Patients receiving continuous NMBA infusion had higher mortality rates (21% vs. 11%, p < 0.001).
  • NMBA use predicted in-hospital mortality (adjusted hazard ratio, 1.6; 95% CI, 1.2-2.1).

Conclusions:

  • Continuous NMBA infusion in mechanically ventilated children is linked to increased in-hospital mortality.
  • Propensity score adjustment confirmed NMBA use as a significant predictor of mortality.
  • Findings suggest cautious use of continuous NMBA infusions in pediatric critical care.
Abstract

Related Concept Videos

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
635
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
412
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.3K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
533
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
692
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
2.1K